[Skip to Navigation]

September 2021 - April 2015

Decade

Year

Issue

May 2021, Vol 7, No. 5, Pages 665-786

Original Investigation

Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials

Abstract Full Text
JAMA Oncol. 2021;7(5):693-699. doi:10.1001/jamaoncol.2021.0006

Two parallel phase 2 nonrandomized clinical trials examine the therapeutic effectiveness of the poly–(adenosine diphosphate–ripose) polymerase inhibitor olaparib for patients with pancreatic cancer with DNA damage repair other than germline BRCA variants.

Safety and Efficacy of Virtual Prostatectomy With Single-Dose Radiotherapy in Patients With Intermediate-Risk Prostate Cancer: Results From the PROSINT Phase 2 Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2021;7(5):700-708. doi:10.1001/jamaoncol.2021.0039

This randomized clinical trial compares toxic effects, prostate-specific antigen responses, and quality-of-life end points of single-dose radiotherapy vs stereotactic body radiotherapy in patients with prostate cancer.

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2021;7(5):709-717. doi:10.1001/jamaoncol.2021.0366

This randomized clinical trial assesses the efficacy and safety of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for patients with advanced squamous non–small-cell lung cancer.

Effectiveness of Electroacupuncture or Auricular Acupuncture vs Usual Care for Chronic Musculoskeletal Pain Among Cancer Survivors: The PEACE Randomized Clinical Trial

Abstract Full Text
has active quiz
JAMA Oncol. 2021;7(5):720-727. doi:10.1001/jamaoncol.2021.0310

This randomized clinical trial explores the effectiveness of electroacupuncture and auricular acupuncture compared with usual care for chronic musculoskeletal pain in cancer survivors.

Evolution of the Randomized Clinical Trial in the Era of Precision Oncology

Abstract Full Text
JAMA Oncol. 2021;7(5):728-734. doi:10.1001/jamaoncol.2021.0379

This cohort study describes contemporary trends in oncology randomized clinical trials (RCTs) and compares these findings with earlier eras of RCT design and output.

Brief Report

Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer

Abstract Full Text
JAMA Oncol. 2021;7(5):735-738. doi:10.1001/jamaoncol.2021.0057

This cohort study examines the use of hypofractionated ablative radiation therapy for patients with locally advanced pancreatic cancer treated with a novel radiation planning and delivery technique.

Response Rates to Anti–PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase

Abstract Full Text
has audio
JAMA Oncol. 2021;7(5):739-743. doi:10.1001/jamaoncol.2020.7684

This cohort study examines the performance of a universal definition of high tumor mutational burden in an independent cohort of patients with solid tumors treated with immune checkpoint inhibitors.

Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma

Abstract Full Text
has audio
JAMA Oncol. 2021;7(5):744-748. doi:10.1001/jamaoncol.2021.0051

This cohort study determines the incidence, time course, spectrum, and associations of chronic immune-related adverse events with adjuvant anti–programmed cell death 1 treatment.

Research Letter

Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma

Abstract Full Text
JAMA Oncol. 2021;7(5):773-775. doi:10.1001/jamaoncol.2021.0019

This cohort study examines treatment with immune checkpoint inhibitors for patients with metastatic renal cell carcinoma.

Association Between Antiangiogenic Drugs Used for Cancer Treatment and Artery Dissections or Aneurysms

Abstract Full Text
JAMA Oncol. 2021;7(5):775-778. doi:10.1001/jamaoncol.2021.0210

This pharmacovigilance study uses data from the World Health Organization database of adverse drug reactions to examine the association of antiangiogenic drugs with artery dissections or aneurysms among patients receiving antiangiogenic drugs for the treatment of cancer.

Review

Current Treatment Strategies and Future Directions for Extrapulmonary Neuroendocrine Carcinomas: A Review

Abstract Full Text
JAMA Oncol. 2021;7(5):759-770. doi:10.1001/jamaoncol.2020.8072

This review addresses the increasing knowledge on tumor biology and neuroendocrine differentiation of other malignant tumors, the current standard of care, and developments in new treatments for small cell lung cancer and extrapulmonary neuroendocrine carcinomas.

JAMA Oncology Clinical Challenge

Asymptomatic Purpuric Eruption on the Scalp of a Middle-aged Man

Abstract Full Text
has active quiz
JAMA Oncol. 2021;7(5):771-772. doi:10.1001/jamaoncol.2020.6773

A man in his 60s with chronic lymphocytic leukemia presents with purpuric rash on his scalp. What is your diagnosis?

Viewpoint

The Role of Temozolomide in Patients With Newly Diagnosed Wild-Type IDH, Unmethylated MGMTp Glioblastoma During the COVID-19 Pandemic

Abstract Full Text
free access
JAMA Oncol. 2021;7(5):675-676. doi:10.1001/jamaoncol.2020.6732

This Viewpoint advocates for a reevaluation of the use of temozolomide for patients with MGMTp unmethylated glioblastomas during the COVID-19 pandemic.

Why Not Adore ADAURA?—The Trial We Need vs the Trial We Got

Abstract Full Text
JAMA Oncol. 2021;7(5):677-678. doi:10.1001/jamaoncol.2020.6752

This Viewpoint explores the application of the results of the ADAURA trial.

Adjuvant Targeted Therapy for Patients With Epidermal Growth Factor Receptor–Mutant Lung Cancer

Abstract Full Text
JAMA Oncol. 2021;7(5):679-680. doi:10.1001/jamaoncol.2020.6755

This Viewpoint discusses the benefits of using adjuvant targeted therapy in earlier stages of cancer based on multiple randomized trials with promising results.

Editorial

JAMA Oncology—The Year in Review, 2020

Abstract Full Text
free access
JAMA Oncol. 2021;7(5):683-684. doi:10.1001/jamaoncol.2021.0094

The 2021 US Preventive Services Task Force Recommendation on Lung Cancer Screening: The More Things Stay the Same…

Abstract Full Text
has audio
JAMA Oncol. 2021;7(5):684-686. doi:10.1001/jamaoncol.2020.8376

Ablative Radiotherapy for Patients With Inoperable Pancreas Cancer—Ready for Prime Time?

Abstract Full Text
JAMA Oncol. 2021;7(5):687-688. doi:10.1001/jamaoncol.2021.0028
Invited Commentary

Tislelizumab—A Promising New Option for Enhancing Chemotherapy Benefit in Treatment for Advanced Squamous Cell Lung Cancer

Abstract Full Text
JAMA Oncol. 2021;7(5):717-719. doi:10.1001/jamaoncol.2021.0262
Cancer Care Chronicles

Last Christmas—Counseling Patients in the Era of COVID-19

Abstract Full Text
free access has active quiz
JAMA Oncol. 2021;7(5):681-682. doi:10.1001/jamaoncol.2021.0125

In this essay, an oncology fellow describes how his conversations with patients with terminal cancer and their families have changed regarding travel and gathering restrictions during the COVID-19 pandemic

Poetry and Oncology

Infiltrating

Abstract Full Text
JAMA Oncol. 2021;7(5):786. doi:10.1001/jamaoncol.2021.0300
Comment & Response

Coffee Consumption and Colorectal Cancer Prognosis

Abstract Full Text
JAMA Oncol. 2021;7(5):778. doi:10.1001/jamaoncol.2020.8479

Coffee Consumption and Colorectal Cancer Prognosis

Abstract Full Text
JAMA Oncol. 2021;7(5):778-779. doi:10.1001/jamaoncol.2020.8485

Coffee Consumption and Colorectal Cancer Prognosis—Reply

Abstract Full Text
JAMA Oncol. 2021;7(5):779-780. doi:10.1001/jamaoncol.2020.8491

Redefining Attribution From Patient to Health System—How the Notion of “Mistrust” Places Blame on Black Patients

Abstract Full Text
JAMA Oncol. 2021;7(5):780. doi:10.1001/jamaoncol.2020.8482

Redefining Attribution From Patient to Health System—How the Notion of “Mistrust” Places Blame on Black Patients—Reply

Abstract Full Text
JAMA Oncol. 2021;7(5):780-781. doi:10.1001/jamaoncol.2020.8494

Combining Machine Learning Predictive Algorithms With Behavioral Nudges to Increase Rates of Serious Illness Conversations in Patients With Cancer

Abstract Full Text
JAMA Oncol. 2021;7(5):781-782. doi:10.1001/jamaoncol.2020.8488

Combining Machine Learning Predictive Algorithms With Behavioral Nudges to Increase Rates of Serious Illness Conversations in Patients With Cancer—Reply

Abstract Full Text
JAMA Oncol. 2021;7(5):782. doi:10.1001/jamaoncol.2020.8499

Stereotactic Ablative Body Radiotherapy for Metastases Needs Better Evidence

Abstract Full Text
JAMA Oncol. 2021;7(5):782-783. doi:10.1001/jamaoncol.2021.0067

Stereotactic Ablative Body Radiotherapy for Metastases Needs Better Evidence—Reply

Abstract Full Text
JAMA Oncol. 2021;7(5):783. doi:10.1001/jamaoncol.2021.0070

The Role of Acute Myeloid Leukemia Minimal Residual Disease in Regulatory Decision-making

Abstract Full Text
JAMA Oncol. 2021;7(5):784. doi:10.1001/jamaoncol.2021.0122

The Role of Acute Myeloid Leukemia Minimal Residual Disease in Regulatory Decision-making—Reply

Abstract Full Text
JAMA Oncol. 2021;7(5):784-785. doi:10.1001/jamaoncol.2021.0128
Correction

Missing Data in Figure

Abstract Full Text
free access
JAMA Oncol. 2021;7(5):785. doi:10.1001/jamaoncol.2021.0352

Error in Funding/Support

Abstract Full Text
free access
JAMA Oncol. 2021;7(5):785. doi:10.1001/jamaoncol.2021.1616
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2021;7(5):665. doi:10.1001/jamaoncol.2020.5061
Peer Reviewers List

JAMA Oncology Peer Reviewers in 2020

Abstract Full Text
free access online only
JAMA Oncol. 2021;7(5):e210146. doi:10.1001/jamaoncol.2021.0146
×